What factors drove the changes in Evolv Technologies's revenue and profit?

What is Evolv Technologies's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Evolv Technologies year over year?

What is the market's earnings forecast for Evolv Technologies next quarter?

What is Evolv Technologies's gross profit margin?

What guidance did Evolv Technologies's management provide for the next earnings period?

What does Evolv Technologies do and what are its main business segments?

Did Evolv Technologies beat or miss consensus estimates last quarter?

- **Revenue Acceleration**: 2026 revenue guidance raised to $172-178 million (18-22% YoY), driven by ARR growth of 20-25% to $145-150 million.
- **Profitability Expansion**: Adjusted EBITDA expected to expand to high single digits in 2026, up from 7.6% in 2025, with gross margin stabilization.
- **Strategic Wins**: 65 new education customers, 35+ sports partnerships, and AHA healthcare certification driving multiyear growth.
- **Product Momentum**: eXpedite adoption in 65 customers, Gen2 upgrades driving 13% RPO growth, and Plexus manufacturing ramp for H2 2026 efficiency gains.
- **Cash Flow Strength**: $69 million cash at year-end, with Q4 collections up $12.8 million sequentially, positioning for H2 2026 cash flow positivity.

### Core Details - Detail Page

**【CEO Summary Section】**
- **Revenue Growth**: Q4 2025 revenue of $38.5 million, up 32% YoY; full-year revenue of $145.9 million, up 40% YoY. ARR reached $120.5 million (21% YoY growth). 
- **Profitability**: Adjusted EBITDA of $11.1 million for the year (vs. -$21 million in 2024), with Q4 margin of 4.7%. Positive cash flow of $69 million at year-end.
- **Market Expansion**: 60+ new customers added in Q4, total customers surpassing 1,200. Key wins in education (65 new school districts), healthcare (partnership with American Hospital Association), and sports (7 new NFL teams).
- **Product Innovation**: eXpedite bag screening solution now deployed in 65 customers, with 16 new customers signing multiproduct contracts. Gen2 Express upgrades driving 13% YoY RPO growth to $293.4 million.
- **2026 Outlook**: Revenue guidance raised to $172-178 million (18-22% YoY growth), ARR expected to reach $145-150 million (20-25% growth). Focus on direct subscription fulfillment and hardware-software integration.

**【CFO Financial Commentary】**
- **Revenue Mix**: Q4 product revenue declined due to one-time large deal, while subscription revenue remained stable. Direct purchase fulfillment model lowers near-term gross margin but increases long-term profitability.
- **Gross Margin**: Q4 adjusted gross margin 50% (vs. 62% YoY), impacted by $1 million field service accrual and direct fulfillment headwinds. Full-year gross profit up $32 million YoY.
- **Operating Expenses**: Q4 adjusted OpEx $23.8 million (3% YoY growth), reflecting 32% revenue growth and operational leverage.
- **Cash Flow**: Sequential increase of $12.8 million to $69 million, driven by collections and working capital management.
- **Long-Term Model**: Targeting high single-digit EBITDA margins in 2026, with gross margin improvements from Plexus manufacturing ramp (expected H2 2026).

**【Q&A Key Highlights】**
- **Revenue Guidance Context**: 2026 ARR growth to outpace revenue growth, with 50-50 mix of purchase subscriptions and pure subscriptions. Q1 2026 revenue boost from record backlog, Q2 decline due to prior-year product backlog consumption.
- **Gross Margin Trends**: 2026 gross margin expected to stabilize or improve slightly, with one-time costs in Q4 2025 (e.g., $1 million service accrual) not recurring.
- **Plexus Production**: Full Gen2 Express production ramp with Plexus expected in H2 2026, with potential gross margin tailwinds.
- **Cash Flow Expectations**: 2026 cash flow positive in H2, with Q1 impacted by $7 million prior-year incentive payments.
- **Hiring Strategy**: Flat headcount vs. 2025, with in-sourcing of external consultants to reduce costs and improve customer engagement.


Evolv Technologies Holdings, Inc.(EVLV)-20260311-2025 Q4 Earnings call transcript

- **Revenue Surge**: Q3 2025 revenue up 57% YoY to $42.9 million, driven by largest contract in company history and direct fulfillment model shift.
- **ARR Inflection**: ARR hits $117.2 million (+25% YoY), with 2026 ARR growth expected to outpace total revenue.
- **eXpedite Success**: New bag scanner added 12 customers in Q3, achieving 2% alert rate and 11/12 cross-sells with Express.
- **Financial Health**: Positive Q3 EBITDA ($5.1M, 12% margin), with full-year 2025 revenue guidance raised to $142-145 million.
- **2026 Vision**: $160-165 million revenue, >20% ARR growth, and strategic deferral of $5-10 million to build recurring streams.

**CEO Summary Section**
- **Revenue Growth**: Q3 2025 revenue of $42.9 million, up 57% YoY, driven by new customer wins (including the largest contract in company history) and expanded deployments. Excluding one-time benefits, normalized growth is ~30% YoY.
- **ARR Expansion**: Annual Recurring Revenue (ARR) reached $117.2 million, +25% YoY, with 2026 expected to mark an inflection point where ARR growth outpaces total revenue growth.
- **Product Momentum**: eXpedite, the autonomous bag screening solution, added 12 new customers in Q3, primarily in education. Early data shows a 2% alert rate, enhancing security efficiency.
- **Strategic Shifts**: Transition from legacy distribution to direct fulfillment model, capturing 100% of ARPU over 4-year subscriptions. This shift defers ~$5-10 million in 2026 revenue but creates long-term recurring streams.
- **Partnership**: New manufacturing partnership with Plexus to scale production and reduce costs over time.

**CFO Financial Commentary**
- **Financial Performance**: Q3 2025 adjusted EBITDA of $5.1 million (12% margin), up from -$3 million in Q3 2024. Full-year 2025 guidance updated to $142-145 million revenue (+37-40% YoY), with EBITDA margins in high single digits.
- **Gross Margin Dynamics**: Q3 gross margin 51%, down from 64% YoY due to direct fulfillment costs and eXpedite ramp-up. Expect 52-54% 2025 gross margin range.
- **Cash Flow**: Sequential cash increase to $56 million, driven by improved collections and a new credit facility.
- **2026 Outlook**: Revenue $160-165 million, ARR growth >20%, with focus on reducing one-time revenue and expanding recurring streams.

**Q&A Key Highlights**
- **Onetime Revenue Impact**: Largest contract contributed $3 million in Q3, with $5+ million expected for 2025. Legacy IP licenses (~$10 million 2025) will decline post-2025.
- **eXpedite Adoption**: 11/12 new eXpedite customers also purchased Express, with strong traction in education (12 new districts) and sports (Carolina Panthers, Buffalo Sabres).
- **Manufacturing Efficiency**: Plexus partnership to reduce COGS over time; eXpedite gross margin expected to improve in 2026.
- **Pipeline Strength**: >50% of bookings from existing customers, with healthy pipeline supporting 2026 unit growth targets.

Evolv Technologies Holdings, Inc. (EVLV) Q3 2025 Earnings Call Transcript

- **Legal Clearance**: DOJ investigation resolved, and class action lawsuit settlement limits direct financial impact to $1M.
- **Revenue Surge**: Q2 revenue up 29% YoY to $32.5M, ARR grows 27% to $110.5M, driven by new customers and Gen2 upgrades.
- **Strategic Shifts**: Transition to direct purchase fulfillment boosts ARR but temporarily lowers gross margin (54-56% H2 guidance).
- **Credit Strength**: $75M credit facility supports subscription growth, with $30M drawn to fund expansion.
- **Market Expansion**: Wins in education (Gwinnett County), healthcare, and sports (Inter Miami CF) highlight cross-vertical momentum.
- **Guidance Uptick**: Full-year revenue growth raised to 27-30%, with positive EBITDA expected for 2025.

**【CEO Summary Section】**
- **Legal Resolution**: The company is no longer under DOJ investigation, and a securities class action lawsuit settlement in principle was reached, with direct financial exposure capped at $1 million.
- **Revenue Growth**: Q2 revenue of $32.5 million, up 29% YoY, driven by new customers and expanding deployments. ARR reached $110.5 million (27% YoY growth).
- **Customer Expansion**: Added over 60 new customers, serving 1,000+ globally. Notable wins include Gwinnett County Public Schools ($15M contract) and healthcare institutions like Ohio State University Wexner Medical Center.
- **Product Momentum**: eXpedite bag screening solution added 8 new customers, bringing total to 20. Gen2 upgrades from existing customers reflect strong retention (54% of booked units from repeat customers).
- **Guidance Update**: Full-year revenue growth raised to 27-30% (from 20-25%), with positive adjusted EBITDA expected for 2025.

**【CFO Financial Commentary】**
- **Financial Highlights**: Adjusted EBITDA of $2M (6% margin), up from -$8M YoY. Sequential cash increase to $37M, first quarter of positive cash flow generation.
- **Gross Margin**: 55% in Q2 (59% YoY), with a 54-56% guidance for H2 due to direct purchase fulfillment and eXpedite scale challenges.
- **Expense Management**: Operating expenses down 19% YoY to $21.6M, reflecting cost optimization.
- **Credit Facility**: Secured $75M non-dilutive credit facility to support subscription model growth, with $30M drawn at close.

**【Q&A Key Highlights】**
- **Sales Mix Shift**: Expecting 50-50 split between subscription and direct purchase models by 2026, with higher ARR from direct sales despite near-term margin headwinds.
- **CPO Program**: Evolv Flex program for refurbished Gen1 units is new, with first orders received but early in execution.
- **Hiring**: Targeted hiring in R&D and services, with no major headcount additions expected.
- **Renewals**: 94% net unit retention in FTC resolution, with 200+ units renewed in Q2, often upgraded to Gen2.
- **Margins**: Long-term gross margin improvement expected as scale benefits offset near-term direct fulfillment costs.

Evolv Technologies (EVLV)-14 Aug 25-2025 Q2 Earnings call transcript

- **Revenue Growth**: Q1 2025 revenue up 44% YoY to $32M, with 34% ARR growth to $106M. 
- **Subscription Momentum**: 50% of Q1 bookings from existing customers, 92% net retention in education. 
- **New Product Success**: eXpedite added 12 customers in first few months. 
- **Financial Health**: Positive Q1 EBITDA ($1.7M), 2025 guidance for $125-130M revenue and positive full-year EBITDA. 
- **Operational Efficiency**: 15% YoY decline in operating expenses, $2M investment in scaling infrastructure. 
- **Market Expansion**: 20/100 largest school districts using Evolv, 500+ healthcare deployments. 
- **Tariff Resilience**: <5% of BOM from China, 40% of BOM from US/Mexico. 


**【CEO Opening Remarks】**
- Q1 2025 revenue: $32 million (10% sequential growth, 44% YoY). ARR reached $106 million (+34% YoY). 
- 50% of Q1 bookings came from existing customers, highlighting strong retention (92% net retention in education sector). 
- Launched **eXpedite**, with 12 new customers in first few months. 
- 2025 revenue guidance: $125-130 million (20-25% growth). 
- 2025 EBITDA target: Positive full-year margin (low to mid-single digits). 
- **CPO Program**: Repurposing retired units to target price-sensitive markets, expected to boost ARR and RPO. 

**【CFO Financial Breakdown】**
- Q1 2025: 
  - Adjusted EBITDA: $1.7 million (5.3% margin). 
  - Gross margin: 61% (stable vs. Q1 2024). 
  - Operating expenses: $23.2 million (-15% YoY). 
- 2025 Outlook: 
  - CapEx: $20-25 million to support subscription growth. 
  - $2 million in near-term investments for operational scaling. 
  - Tariff impact: <5% of bill of materials, minimal direct risk due to US manufacturing. 

**【Q&A Highlights】**
1. **Market Expansion**: 
   - Healthcare: California mandate for hospital weapons detection (23 knives flagged in 1 week). 
   - Education: 20/100 largest US school districts using Evolv. 
2. **Product Mix**: 
   - Shifting to pure subscriptions (48-month leases) vs. purchase deals, reducing upfront revenue but boosting ARR visibility. 
   - Gen 2 Express: Lower China component dependency (40% of BOM from US/Mexico). 
3. **Customer Acquisition**: 
   - 50% of Q1 units booked from existing customers. 
   - 950 total customers across education, healthcare, sports. 
   - 400 units up for renewal in 2025, with 92% retention in eligible education contracts. 


Actual	-0.71	0.15	0.02	-0.1	-0.12	-0.13	-0.12	-0.12	-0.1	-0.08	-0.07	-0.09	-0.06	-0.07	-0.03	-0.02	-0.02	-0.02	-0.03
Forecast	-0.17	-0.1125	-0.1033	-0.1175	-0.13	-0.14	-0.1275	-0.1375	-0.1175	-0.11	-0.0925	-0.0867	-0.0875	-0.08	-0.0733	-0.045	-0.035	-0.0333	-0.0375
Surprise	-317.65%	+233.33%	+119.36%	+14.89%	+7.69%	+7.14%	+5.88%	+12.73%	+14.89%	+27.27%	+24.32%	-3.81%	+31.43%	+12.50%	+59.07%	+55.56%	+42.86%	+39.94%	+20.00%

EVLV

EVLV fundamentals

EVLV Q4 2025 Earnings

Earnings Call

You can ask Aime

EVLV

EVLV fundamentals

EVLV Q4 2025 Earnings

Earnings Call

EVLV Earnings Call Summary for Q4/20254:30 PM on Mar 10, 2026

EVLV Earnings Call Summary for Q3/20254:30 PM on Nov 13, 2025

EVLV Earnings Call Summary for Q2/20254:30 PM on Aug 14, 2025

EVLV Earnings Call Summary for Q1/20254:30 PM on May 20, 2025

EVLV Earnings Call Summary for Q4/20245:00 PM on Apr 28, 2025

You can ask Aime